ArticleFrontiers in oncology2019
Versican and Tumor-Associated Macrophages Promotes Tumor Progression and Metastasis in Canine and Murine Models of Breast Carcinoma.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 38 citations in OpenAlex.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Negative regulators antagonizing antitumor innate immune pathways in lung cancer immune evasion.Frontiers in immunology · 2026Review
- Proteoglycans in Breast Cancer: Friends and Foes.Biomolecules · 2025Review
- Article
- Canine, Feline, and Murine Mammary Tumors as a Model for Translational Research in Breast Cancer.Veterinary sciences · 2025Review
- A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma.American journal of cancer research · 2025Article
- Multi-Omics Insights into the Impact of MDH2 on Breast Cancer Progression: A Promising Druggable Target.Oncology research · 2025Article
- Infiltration of innate and adoptive lymphoid cells in 4T1 and MC4-L2 breast cancer models.Iranian journal of basic medical sciences · 2025Article
- Screening and validating the optimal panel of housekeeping genes for 4T1 breast carcinoma and metastasis studies in mice.Scientific reports · 2024Article
- Plasma versican and plasma exosomal versican as potential diagnostic markers for non-small cell lung cancer.Respiratory research · 2023Article
- Article
- VCAN Hypomethylation and Expression as Predictive Biomarkers of Drug Sensitivity in Upper Urinary Tract Urothelial Carcinoma.International journal of molecular sciences · 2023Article
- Article
- Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors.Veterinary sciences · 2022Review
- Matrix proteoglycans in tumor inflammation and immunity.American journal of physiology. Cell physiology · 2022Review
- Identification of Hub Genes Associated with the Pathogenesis of Intracranial Aneurysm via Integrated Bioinformatics Analysis.International journal of general medicine · 2021Article
- A Zebrafish Model of Metastatic Colonization Pinpoints Cellular Mechanisms of Circulating Tumor Cell Extravasation.Frontiers in oncology · 2021Article
- Upregulation of Versican Associated with Tumor Progression, Metastasis, and Poor Prognosis in Bladder Carcinoma.BioMed research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Versican and tumor-associated macrophages (TAMs) are involved in growth and metastases in several cancers. Here, we investigated the potential role of versican, a matrix proteoglycan, and its correlation with TAMs infiltrates in different stages of two different breast cancer models: spontaneous canine mammary gland carcinomas and the murine 4T1 breast cancer model. The stromal versican expression was correlated with TAMs accumulation in tumors with an advanced stage from spontaneous canine mammary carcinoma samples. Versican expression in mice, identified in late stages of tumor progression, was associated to a high number of peri-tumoral infiltrating TAMs. Indeed, TAMs were related to a pro-inflammatory and pro-angiogenic state in the primary tumor. Furthermore, TAMs accumulation was related to versican expression in the lungs and an increased number of pulmonary metastatic nodules with pulmonary mechanical dysfunction, which was due to leukocyte influx in the airways and elevated growth factor levels in the microenvironment. Thus, we suggest that versican and TAMs as attractive targets for breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.